These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 9563896

  • 1. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN, Yang L, Tang C, Yang D, Lupu R.
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [Abstract] [Full Text] [Related]

  • 2. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
    Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS.
    Clin Cancer Res; 2001 Jun; 7(6):1497-504. PubMed ID: 11410482
    [Abstract] [Full Text] [Related]

  • 3. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES.
    Oncol Res; 1996 Jun; 8(3):101-10. PubMed ID: 8823806
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
    Zhou Z, Zwelling LA, Kawakami Y, An T, Kobayashi K, Herzog C, Kleinerman ES.
    Cancer Res; 1999 Sep 15; 59(18):4618-24. PubMed ID: 10493516
    [Abstract] [Full Text] [Related]

  • 5. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec 15; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 6. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK.
    Breast Cancer Res Treat; 2005 Jul 15; 92(1):69-75. PubMed ID: 15980993
    [Abstract] [Full Text] [Related]

  • 7. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y, Takano H, Nagao S, Fojo T.
    Jpn J Cancer Res; 2001 Sep 15; 92(9):968-74. PubMed ID: 11572765
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ, White RL, Matsunami N, Neufeld KL.
    Cancer Res; 2000 Dec 15; 60(24):6989-94. PubMed ID: 11156401
    [Abstract] [Full Text] [Related]

  • 9. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
    Kawanami K, Nakamura T, Ono M, Kusano T, Okada K, Kikuchi A, Adachi N, Kohno K, Higashi K, Kuwano M.
    Oncol Res; 1996 Dec 15; 8(5):197-206. PubMed ID: 8884812
    [Abstract] [Full Text] [Related]

  • 10. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG, Lange J, Kett A, Dornhöfer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F, Tanner B.
    Cancer Res; 1999 Jul 01; 59(13):3206-14. PubMed ID: 10397267
    [Abstract] [Full Text] [Related]

  • 11. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S, Gomez SP, McCarley D, Mainwaring MG.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):347-55. PubMed ID: 11976828
    [Abstract] [Full Text] [Related]

  • 12. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
    Zhu L, Li YF, Chen WG, He JR, Peng CH, Zhu ZG, Li HW.
    Chin Med J (Engl); 2008 Oct 20; 121(20):1965-8. PubMed ID: 19080257
    [Abstract] [Full Text] [Related]

  • 13. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Asano T, Kleinerman ES, Zwelling LA, Zhou Z, Fukunaga Y.
    Acta Oncol; 2005 Oct 20; 44(3):240-7. PubMed ID: 16076696
    [Abstract] [Full Text] [Related]

  • 14. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL.
    Cancer Res; 2000 Oct 15; 60(20):5747-53. PubMed ID: 11059769
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 15; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 16. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
    Zhou Z, Guan H, Kleinerman ES.
    Mol Cancer Res; 2005 May 15; 3(5):271-5. PubMed ID: 15886298
    [Abstract] [Full Text] [Related]

  • 17. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD.
    Clin Cancer Res; 2002 Apr 15; 8(4):1061-7. PubMed ID: 11948114
    [Abstract] [Full Text] [Related]

  • 18. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.
    Cancer Treat Rev; 2009 Dec 15; 35(8):662-7. PubMed ID: 19758759
    [Abstract] [Full Text] [Related]

  • 19. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.
    Cancer Chemother Pharmacol; 2004 Feb 15; 53(2):155-62. PubMed ID: 14504921
    [Abstract] [Full Text] [Related]

  • 20. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
    Zhou Z, Jia SF, Hung MC, Kleinerman ES.
    Cancer Res; 2001 Apr 15; 61(8):3394-8. PubMed ID: 11309298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.